The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura

NACompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

June 14, 2020

Primary Completion Date

May 31, 2022

Study Completion Date

June 30, 2022

Conditions
Purpura, Schoenlein-Henoch
Interventions
DRUG

IL-2

For all patients,rhIL-2 infusions seven days;recurrent patients was applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months.

Trial Locations (1)

130021

Sirui Yang, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT04387942 - The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura | Biotech Hunter | Biotech Hunter